Albumin-binding interactions of sodium valproate

Area of Science:

• Pharmacology
• Biochemistry

Background:

• Valproate is an antiepileptic drug with a narrow therapeutic index.
• Drug interactions affecting valproate protein binding can alter its efficacy and toxicity.

Purpose of the Study:

• To investigate the in vitro effect of common therapeutic agents on valproate binding to human serum albumin.

Main Methods:

• Equilibrium dialysis was employed to assess the binding of valproate to human serum albumin.
• The displacement effects of salicylate, phenylbutazone, warfarin, and carbamazepine on valproate binding were evaluated at therapeutic concentrations.

Main Results:

• Salicylate and phenylbutazone significantly displaced valproate from its albumin binding sites.
• Warfarin and carbamazepine did not demonstrate a significant effect on valproate-albumin binding.

Conclusions:

• Co-administration of valproate with salicylate or phenylbutazone may lead to altered pharmacokinetics due to changes in protein binding.
• Clinicians should consider potential drug interactions when prescribing these agents concurrently with valproate.